The most pronounced delays in tumor progression for both 4T1 and E0771 breast tumor models were observed when the treatment protocol combined ketotifen, sonopermeation, Doxil, and immune checkpoint inhibitors (ICIs), specifically anti-PD-1 and anti-CTLA-4 antibodies. Here, CTLA4 is linked to breast neoplasm.